AI-powered search

Featured Poster: Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib through Week 48 in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

In this poster presented at the 2023 Fall Clinical Dermatology Conference for PAs & NPs in Orlando, Piliang and colleagues evaluate scalp, eyebrow, and eyelash hair regrowth in patients treated with ritlecitinib

By Dermsquared Editorial Team | June 16, 2023

Click here to view poster PDF

Ritlecitinib is an oral JAK3/TEC family kinase inhibitor used for the treatment of alopecia areata in patients 12 years and older. In the ALLEGRO phase 2b/3 trial, ritlecitinib demonstrated significant improvements in the proportion of patients with Severity of Alopecia Tool (SALT) score ≤20 at week 24.

This poster presents a post hoc analysis evaluating sustained scalp, eyebrow, and eyelash hair regrowth over 48 weeks in ritlecitinib-treated patients who had a clinical response at week 24. There were 4 different doses studied, including 200 mg QD loading doses over 4 weeks followed by 30 or 50 mg QD, or 30 or 50 mg QD without a loading dose. 
For those who achieved SALT score ≤20 at week 24, 85.2% to 100% maintained this score through week 48, depending on the dose.


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved